Phibro Animal Health (NASDAQ:PAHC) Upgraded by Zacks Investment Research to “Hold”

0
3

Phibro Animal Health (NASDAQ:PAHC) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday, Zacks.com reports. The firm presently has a $23.00 price target on the stock. Zacks Investment Research‘s price target points to a potential upside of 9.37% from the stock’s current price.

According to Zacks, “In the first quarter of fiscal 2021, strength in Animal Health and Performance Products arms boosted the overall top line for Phirbo. Robust nutritional specialty product and net vaccine sales were impressive. Strong international performance amid the pandemic-led challenging business climate looks impressive. Ongoing business recovery due to strong customer demand looks encouraging. Expansion of both margins raise optimism. A strong balance sheet position is an added plus.  On the flip side, dismal show by Phibro’s Mineral Nutrition arm in the first quarter of fiscal 2021 is concerning. Lower sales of the Performance Products arm’s copper-based products raise concerns. Foreign exchange fluctuations and stiff competition persist. Phibro has underperformed its industry for the past six months.”

Separately, ValuEngine raised shares of Phibro Animal Health from a “sell” rating to a “hold” rating in a report on Tuesday, December 1st. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $23.80.

(Ad)

They called the 2020 crash 45 days early. Nobody expects what they’re predicting now…

Shares of NASDAQ PAHC traded up $0.14 during midday trading on Monday, hitting $21.03. 963 shares of the company’s stock were exchanged, compared to its average volume of 125,460. The company’s 50 day moving average price is $19.06 and its 200 day moving average price is $20.14. The firm has a market capitalization of $850.73 million, a PE ratio of 25.52, a price-to-earnings-growth ratio of 1.56 and a beta of 0.37. Phibro Animal Health has a 12 month low of $16.27 and a 12 month high of $29.38. The company has a quick ratio of 1.62, a current ratio of 2.87 and a debt-to-equity ratio of 1.96.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings data on Monday, November 9th. The company reported $0.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.21 by $0.06. The firm had revenue of $195.20 million during the quarter. Phibro Animal Health had a return on equity of 21.69% and a net margin of 4.19%. On average, equities research analysts anticipate that Phibro Animal Health will post 1.15 EPS for the current year.

Several institutional investors have recently made changes to their positions in the company. Bank of Montreal Can raised its position in shares of Phibro Animal Health by 80.2% during the 2nd quarter. Bank of Montreal Can now owns 2,725 shares of the company’s stock valued at $67,000 after buying an additional 1,213 shares during the period. California Public Employees Retirement System lifted its position in Phibro Animal Health by 3.1% during the 3rd quarter. California Public Employees Retirement System now owns 46,479 shares of the company’s stock valued at $809,000 after purchasing an additional 1,400 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Phibro Animal Health by 4.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 65,500 shares of the company’s stock worth $1,137,000 after acquiring an additional 2,518 shares in the last quarter. Advisors Asset Management Inc. lifted its stake in Phibro Animal Health by 14.9% in the third quarter. Advisors Asset Management Inc. now owns 20,066 shares of the company’s stock valued at $349,000 after buying an additional 2,601 shares during the period. Finally, Globeflex Capital L P increased its position in shares of Phibro Animal Health by 4.3% during the 3rd quarter. Globeflex Capital L P now owns 65,809 shares of the company’s stock valued at $1,145,000 after purchasing an additional 2,740 shares during the last quarter.

About Phibro Animal Health

Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture.

Read More: What is the NASDAQ Stock Market?

Get a free copy of the Zacks research report on Phibro Animal Health (PAHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Phibro Animal Health (NASDAQ:PAHC)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

15 Stocks that Insiders Love

An insider trade occurs when a corporate executive (such as a CEO, CFO or COO) that has non-public information about a company buys or sells shares of that company’s stock. Company insiders are required by law to regularly report their stock purchases and sales to the SEC.

Tracking a company’s insider trades is a metric that can be used to identify the direction that the company’s executives believes that the company is headed. If a number of insiders purchase more shares of their company, they may believe that the company will have strong future earnings and that the share price will increase in the near future.

For example, if Microsoft’s CEO, CFO and COO all recently purchased additional shares of Microsoft stock, that would be an indication that there could be unreported news that may positively effect Microsoft’s stock price in the near future.

This slideshow lists the 15 companies that have had the highest levels of insider buying within the last 180 days.

View the “15 Stocks that Insiders Love”.

LEAVE A REPLY

Please enter your comment!
Please enter your name here